Evidence map›Paper›PMID 31737007›Full record

ArticleFrontiers in plant science2019

Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens.

Emmanuel Margolin, Rosamund Chapman, Ann E Meyers, Michiel T van Diepen, Phindile Ximba, Tandile Hermanus, Carol Crowther, Brandon Weber, Lynn Morris, Anna-Lise Williamson and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in plant science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Emmanuel MargolinDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Rosamund ChapmanDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Ann E MeyersBiopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa.
Michiel T van DiepenDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Phindile XimbaDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Tandile HermanusNational Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, South Africa.
Carol CrowtherNational Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, South Africa.
Brandon WeberStructural Biology Research Unit, Division of Medical Biochemistry, Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa.
Lynn MorrisNational Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham, South Africa.
Anna-Lise WilliamsonDivision of Medical Virology, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
Edward P RybickiBiopharming Research Unit, Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South Africa.
University of Cape Town · ZAUniversity of the Witwatersrand · ZANational Health Laboratory Service · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of effective vaccines is urgently needed to curb the spread of human immunodeficiency virus type 1 (HIV-1). A major focal point of current HIV vaccine research is the production of soluble envelope (Env) glycoproteins which reproduce the structure of the native gp160 trimer. These antigens are produced in mammalian cells, which requires a sophisticated infrastructure for manufacture that is mostly absent in developing countries. The production of recombinant proteins in plants is an attractive alternative for the potentially cheap and scalable production of vaccine antigens, especially for developing countries. In this study, we developed a transient expression system in

Indexed as

glycoproteinHIVimmunogenicitymodified vaccinia Ankaraplants

Identifiers

PMID31737007
PMCPMC6831737
OpenAlexW2981505029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.